Charlotte C. Sun, Dr.P.H., M.P.H.

Peer-Reviewed Articles

1. Brodsky, AL, Sun, CC, Cobb, LP, Westin, SN, Malpica, A, Gershenson, DM. Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon. Gynecologic oncology 200:130-136, 2025. e-Pub 2025. PMID: 40749518.
2. Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prev Res (Phila) 18(5):299-306, 2025. e-Pub 2025. PMID: 39930864.
3. Adjei, N, Haas, A, Sun, CC, Zhao, H, Yeh, PG, Giordano, SH, Toumazis, I, Meyer, LA. Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status. Value in Health 28(2):206-214, 2025. e-Pub 2025. PMID: 39532216.
4. Adjei NN, Haas AM, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol 232(2):204.e1-204.e13, 2025. e-Pub 2025. PMID: 39159781.
5. Adjei NN, Haas A, Zhao H, Primm KM, Giordano SH, Sun CC, Meyer LA. Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol 190:255-261, 2024. e-Pub 2024. PMID: 39260122.
6. Primm, K, Zhao, H, Adjei, N, Sun, CC, Haas, A, Meyer, LA, Chang, S. Effect of Medicaid expansion on cancer treatment and survival among Medicaid beneficiaries and the uninsured. Cancer medicine 13(13), 2024. e-Pub 2024. PMID: 38970338.
7. Suidan RS, Sun CC, Schneider AK, Lu KH, Giordano SH, Meyer LA. Determination of quality of life-related health utilities for surgical complications in ovarian cancer. Gynecol Oncol 185:101-107, 2024. e-Pub 2024. PMID: 38377761.
8. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2024. PMID: 38009662.
9. Vranes C, Zhao H, Noer MC, Fu S, Sun CC, Harrison R, Ramirez PT, Høgdall CK, Giordano SH, Meyer LA. Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Int J Gynecol Cancer 33(5):749-754, 2023. e-Pub 2023. PMID: 36863760.
10. Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. ASO Visual Abstract: Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer-A Difference-in-Difference Analysis. Ann Surg Oncol 30(3):1520-1521, 2023. e-Pub 2023. PMID: 36289120.
11. Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. Medicaid Expansion and Postoperative Mortality in Women with Gynecologic Cancer: A Difference-in-Difference Analysis. Ann Surg Oncol 30(3):1508-1519, 2023. e-Pub 2023. PMID: 36310311.
12. Prescott LS, Vergote I, Sun CC, Bodurka DC, Coleman RL. Transfusion use and effect on progression-free, overall survival, and quality of life in upfront treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 Cohort. Int J Gynecol Cancer 33(1):1-9, 2023. e-Pub 2023. PMID: 36356982.
13. Primm K, Huepenbecker S, Zhao H, Sun CC, Hernandez DC, Meyer LA, Chang S. Impacts of Medicaid Expansion on Stage at Cancer Diagnosis by Patient Insurance Type. American Journal of Preventive Medicine 63(6):915-925, 2022. e-Pub 2022. PMID: 35871117.
14. Gibbons C, Sun CC, Schneider A, Lu S, Lu KH, Wright AA, Meyer LA. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. Scientific reports 12(1), 2022. e-Pub 2022. PMID: 36481644.
15. Wong, KK, Bateman, NW, Ng, CW, Tsang, YT, Sun, CC, Celestino, J, Nguyen, T, Malpica, A, Hillman, RT, Zhang, J, Futreal, A, Rojas, C, Conrads, KA, Hood, BL, Dalgard, C, Wilkerson, MD, Phippen, NT, Conrads, TP, Maxwell, GL, Sood, AK, Gershenson, DM. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Journal of translational medicine 20(1), 2022. e-Pub 2022. PMID: 36528667.
16. Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol 167(2):139-145, 2022. e-Pub 2022. PMID: 36137845.
17. Huepenbecker SP, Fu S, Sun CC, Zhao H, Primm KM, Giordano SH, Meyer LA. Medicaid expansion and 2-year survival in women with gynecologic cancer: a difference-in-difference analysis. Am J Obstet Gynecol 227(3):482.e1-482.e15, 2022. e-Pub 2022. PMID: 35500609.
18. Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Rauh-Hain JA, Fleming ND, Giordano SH, Meyer LA. Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States. Int J Gynecol Cancer 32(9):1153-1163, 2022. e-Pub 2022. PMID: 36166208.
19. Huepenbecker SP, Sun CC, Fu S, Zhao H, He W, Primm K, Giordano SH, Meyer LA. Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States. Int J Gynecol Cancer 32(7):899-905, 2022. e-Pub 2022. PMID: 35331992.
20. Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
21. Huepenbecker, S, Zhao, H, Sun, CC, Fu, S, He, W, Giordano, SH, Meyer, LA. Algorithm to Identify Incident Epithelial Ovarian Cancer Cases Using Claims Data. JCO Clinical Cancer Informatics 6, 2022. e-Pub 2022. PMID: 35297648.
22. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
23. Huepenbecker SP, Sun CC, Fu S, Zhao H, Primm K, Giordano SH, Meyer LA. Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States. Cancer 127(22):4151-4160, 2021. e-Pub 2021. PMID: 34347287.
24. Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer LA. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. Am J Obstet Gynecol 225(1):68.e1-68.e11, 2021. e-Pub 2021. PMID: 33549538.
25. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 161(1):56-62, 2021. e-Pub 2021. PMID: 33536126.
26. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol 224(2):191.e1-191.e15, 2021. e-Pub 2021. PMID: 32805208.
27. Gershenson DM, Cobb LP, Sun CC. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gynecol Oncol 159(3):601-603, 2020. e-Pub 2020. PMID: 33019983.
28. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol 158(3):653-658, 2020. e-Pub 2020. PMID: 32709538.
29. Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, Lu KH, Giordano SH, Meyer LA. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. Int J Gynecol Cancer 30(8):1195-1202, 2020. e-Pub 2020. PMID: 32616627.
30. Bednar EM, Sun CC, McCurdy S, Vernon SW. Assessing relatives' readiness for hereditary cancer cascade genetic testing. Genet Med 22(4):719-726, 2020. e-Pub 2020. PMID: 31857708.
31. Harrison R, Zhao H, Sun CC Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. Int J Gynecol Cancer 30(2):187-192, 2020. e-Pub 2020. PMID: 31843871.
32. Harrison RF, He W, Fu S, Zhao H, Sun CC Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. National Patterns of Care and Fertility Outcomes for Reproductive-aged Women with Endometrial Cancer or Atypical Hyperplasia. Am J Obstet Gynecol 221(5):474.e1-474.e11, 2019. e-Pub 2019. PMID: 31128110.
33. Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, Lu KH, Giordano SH, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am J Obstet Gynecol 221(2):136.e1-136.e9, 2019. e-Pub 2019. PMID: 30965052.
34. Dottino JA, He W, Sun CC, Zhao H, Fu S, Lu KH, Meyer LA. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. Gynecol Oncol 154(2):405-410, 2019. e-Pub 2019. PMID: 31208738.
35. Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. Gynecol Oncol 152(3):439-444, 2019. e-Pub 2019. PMID: 30876486.
36. Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun CC, Wang XS, Lu KH, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. Gynecol Oncol 152(3):501-508, 2019. e-Pub 2019. PMID: 30876495.
37. Sun CC, Meyer LA, Daniels MS, Bodurka DC, Nebgen DR, Burton-Chase AM, Lu KH, Peterson SK. Women's preferences for cancer risk management strategies in Lynch Syndrome. Gynecol Oncol 152(3):514-521, 2019. e-Pub 2019. PMID: 30876497.
38. Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. Gynecol Oncol 152(2):328-333, 2019. e-Pub 2019. PMID: 30528888.
39. Taylor JS, He W, Harrison R, Zhao H, Sun CC, Lu KH, Giordano SH, Meyer LA. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecol Oncol 151(2):269-274, 2018. e-Pub 2018. PMID: 30253875.
40. Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, Lu KH, Giordano SH. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol 150(3):451-459, 2018. e-Pub 2018. PMID: 29961559.
41. Burton-Chase A, Hovick S, Sun CC, Boyd-Rogers S, Lynch P, Lu K, Peterson S. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet, 2018. e-Pub 2018. PMID: 23906188.
42. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, Lu KH. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol Oncol 150(1):79-84, 2018. e-Pub 2018. PMID: 29735278.
43. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Three lymphadenectomy strategies in low-risk endometrial carcinoma: a cost-effectiveness analysis. Obstet Gynecol 132(1):52-58, 2018. e-Pub 2018. PMID: 29889752.
44. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, Soliman PT. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol 149(3):484-490, 2018. e-Pub 2018. PMID: 29622276.
45. Schlumbrecht M, Sun CC, Huang M, Milbourne A, Bodurka D. Gynecologic cancer survivor preferences for long-term surveillance. BNC Cancer Apr 3(18 (1)):375, 2018. e-Pub 2018. PMID: 29614979.
46. Shah JS, Guerra R, Bodurka DC, Sun CC, Chisholm GB, Woodard TL. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. Gynecol Oncol 147(3):497-502, 2017. e-Pub 2017. PMID: 28941656.
47. Suidan RS, He W, Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer LA. Treatment patterns, outcomes, and costs for bowel obstruction in ovarian cancer. Int J Gynecol Cancer 27(7):1350-1359, 2017. e-Pub 2017. PMID: 28574929.
48. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, Lu KH. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 146(2):234-239, 2017. e-Pub 2017. PMID: 28528918.
49. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, Lu KH. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Gynecol Oncol 146(2):399-404, 2017. e-Pub 2017. PMID: 28610746.
50. Brown AJ, Thaker PH, Sun CC, Urbauer DL, Bruera E, Bodurka DC, Ramondetta LM. Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer 25(6):1985-1991, 2017. e-Pub 2017. PMID: 28175997.
51. Brown AJ, Shen MJ, Urbauer D, Taylor J, Parker PA, Carmack C, Prescott L, Rosemore C, Kolawole E, Sun CC, Ramondetta L, Bodurka DC. The advance care planning readiness scale: Development and validation of a measure of willingness to discuss and acceptance of end-of-life care in gynecologic cancer patients. Int J Gynecol Cancer 27(4):838-846, 2017. e-Pub 2017. PMID: 28399031.
52. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol 35(10):1103-1111, 2017. e-Pub 2017. PMID: 28221866.
53. Dalton HJ, Fleming ND, Sun CC, Bhosale P, Schmeler KM, Gershenson DM. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol 145(1):37-40, 2017. e-Pub 2017. PMID: 28139261.
54. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol 145(1):55-60, 2017. e-Pub 2017. PMID: 28131529.
55. Taylor JS, Marten CA, Munsell MF, Sun CC, Potts KA, Burzawa JK, Nick AM, Meyer LA, Myers K, Bodurka DC, Aloia TA, Levenback CF, Lairson DR, Schmeler KM. The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTions in Gynecologic Oncology. Ann Surg Oncol 24(2):362-368, 2017. e-Pub 2017. PMID: 27573526.
56. Iglesias DA, Zhang Q, Celestino J, Sun CC, Yates MS, Schmandt RE, Lu KH. Lean body weight and metformin are insufficient to prevent endometrial hyperplasia in mice harboring inactivating mutations of PTEN. Oncology 92(2):109-114, 2017. e-Pub 2017. PMID: 27931017.
57. Esselen KM, Cronin AM, Bixel K, Bookman MA, Burger RA, Cohn DE, Cristea M, Griggs JJ, Levenback CF, Mantia-Smaldone G, Meyer LA, Matulonis UA, Niland JC, Sun CC, O'Malley DM, Wright AA. Use of CA-125 tests and computed tomographic scans for surveillance in ovarian cancer. JAMA 1(2(11)):1427-1433, 2016. e-Pub 2016. PMID: 27442965.
58. Pakish JB, Lu KH, Sun CC, Burzawa JK, Greisinger A, Smith FA, Fellman B, Urbauer DL, Soliman PT. Endometrial cancer associated symptoms: A case-control study. J Womens Health (Larchmt) 25(11):1187-1192, 2016. e-Pub 2016. PMID: 27254529.
59. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. J Clin Oncol, 2016. e-Pub 2016. PMID: 27601552.
60. Brown AJ, Shen MJ, Urbauer D, Taylor J, Parker PA, Carmack C, Prescott L, Kolawole E, Rosemore C, Sun CC, Ramondetta L, Bodurka DC. Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Onco 142(3):525-530, 2016. e-Pub 2016. PMID: 27439968.
61. Ganeshan D, Bhosale P, Wei W, Ramalingam P, Mudasiru-Dawodu E, Gershenson D, Sun CC, Iyer R. Increase in post-therapy tumor calcification on CT scan is not an indicator of response to therapy in low-grade serous ovarian cancer. Abdom Radiol (NY) 41(8):1589-1595, 2016. e-Pub 2016. PMID: 26969496.
62. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, Lu KH, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. J Cancer Surviv 10(2):261-70, 2016. e-Pub 2016. PMID: 26245979.
63. Taylor JS, Brown AJ, Prescott LS, Sun CC, Ramondetta LM, Bodurka DC. Dying well: How equal is end of life care among gynecologic oncology patients?. Gynecol Oncol 140(2):295-300, 2016. e-Pub 2016. PMID: 26706661.
64. Ramondetta LM, Meyer LA, Schmeler KM, Daheri ME, Gallegos J, Scheurer M, Montealegre JR, Milbourne A, Anderson ML, Sun CC. Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer. Gynecol Oncol 139(3):500-5, 2015. e-Pub 2015. PMID: 26498912.
65. Kim YJ, Munsell MF, Park JC, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Williams JL, Chase DM, Bruera E, Ramondetta LM. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol 139(3):553-8, 2015. e-Pub 2015. PMID: 26432043.
66. Gershenson DM, Sun CC, Wong KK. Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum. Br J Cancer 113(9):1254-8, 2015. e-Pub 2015. PMID: 26484411.
67. Arms RG, Sun CC, Burzawa JK, Fleming ND, Nick AM, Rallapalli V, Westin SN, Meyer LA, Ramirez PT, Soliman PT. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol 138(3):727-30, 2015. e-Pub 2015. PMID: 26197762.
68. Brown AJ, Sun CC, Urbauer DL, Bodurka DC, Thaker PH, Ramondetta LM. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol 138(2):388-93, 2015. e-Pub 2015. PMID: 25988961.
69. Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: Results of a large single-institution registry of a rare tumor. J Clin Oncol 33(24):2675-82, 2015. e-Pub 2015. PMID: 26195696.
70. Brown AJ, Sun CC, Urbauer D, Zhukovsky DS, Levenback C, Frumovitz M, Thaker PH, Bodurka DC, Ramondetta LM. Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23(7):2025-32, 2015. e-Pub 2015. PMID: 25519758.
71. Brown J, Taylor K, Ramirez PT, Sun CC, Holman LL, Cone SM, Irwin J, Frumovitz M. Laparoscopic supracervical hysterectomy with morcellation: should it stay or should it go?. J Minim Invasive Gynecol, 2015. e-Pub 2015. PMID: 25242233.
72. Crane EK, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer. Gynecol Oncol 136(1):25-9, 2015. e-Pub 2015. PMID: 25448453.
73. Prescott LS, Aloia TA, Brown AJ, Taylor JS, Munsell MF, Sun CC, Schmeler KM, Levenback CF, Bodurka DC. Perioperative blood transfusion in gynecologic oncology surgery: Analysis of the National Surgical Quality Improvement Program Database. Gynecol Oncol, 2015. e-Pub 2015. PMID: 25451693.
74. Brown AJ, Sun CC, Prescott LS, Taylor JS, Ramondetta LM, Bodurka DC. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol, 2014. e-Pub 2014. PMID: 25192878.
75. Burton-Chase, Hovick S, Sun CC, Boyd-Rogers S, Lynch P, Lu K, Peterson S. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. Clin Genet, 2014. e-Pub 2014. PMID: 23906188.
76. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD. Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010). Eur J Cancer, 2014. e-Pub 2014. PMID: 24857045.
77. Sun CC, Brown AJ, Jhingran A, Frumovitz M, Ramondetta L, Bodurka DC. Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer, 2014. e-Pub 2014. PMID: 24905618.
78. Bruegl AS, Djordjevic B, Batte B, Daniels MS, Fellman BM, Urbauer DL, Luthra R, Sun C, Lu K, Broaddus RR. Evaluation of Clinical Criteria for the Identification of Lynch Syndrome among Unselected Endometrial Cancer Patients. Cancer Prev Res, 2014. e-Pub 2014. PMID: 24771847.
79. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of Prophylactic Salpingectomy with Delayed Oophorectomy as Risk-Reducing Surgery Among BRCA Mutation Carriers. Gynecol Oncol, 2014. e-Pub 2014. PMID: 24582866.
80. Schlumbrecht MP, Sun CC, Huang MS, Zandstra F, Bodurka DC. Lifestyle modification in cervical cancer survivors: an ongoing need. Int J Gynecol Cancer 24(3):570-575, 2014. e-Pub 2014. PMID: 24469324.
81. Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk Perception, Worry, and Test Acceptance in Average-Risk Women Undergoing Ovarian Cancer Screening. Am J Obstet Gynecol 210(3), 2014. e-Pub 2014. PMID: 24246524.
82. Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma. J Pathol 231(4):449-56, 2013. e-Pub 2013. PMID: 24549645.
83. Williams LA, Agarwal S, Bodurka DC, Saleeba AK, Sun CC, Cleeland CS. Capturing the Patient's Experience: Using Qualitative Methods to Develop a Measure of Patient-Reported Symptom Burden: An Example From Ovarian Cancer. J Pain Symptom Manage 46(6):837-845, 2013. e-Pub 2013. PMID: 23615044.
84. Ramondetta LM, Sun CC, Surbone A, Olver I, Ripamonti C, Konishi T, Baider L, Johnson J. Surprising results regarding MASCC members' beliefs about spiritual care. Support Care Cancer, 2013. e-Pub 2013. PMID: 23775154.
85. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 119(19):3454-61, 2013. e-Pub 2013. PMID: 23983047.
86. Likhacheva A, Jhingran A, Bodurka DC, Sun CC, Sam M, Eifel PJ. Prospective Study of Symptom Assessment Among Patients With Cervical Cancer During Concurrent Chemoradiotherapy With Weekly Cisplatin or Every-3-Week Cisplatin and 5-Fluorouracil. Int J Gynecol Cancer 23(8):1520-1527, 2013. e-Pub 2013. PMID: 24257567.
87. Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-grade serous carcinoma: New concepts and emerging therapies. Gynecol Oncol, 2013. e-Pub 2013. PMID: 23707670.
88. Huang M, Djordjevic B, Yates MS, Urbauer D, Sun CC, Burzawa J, Daniels M, Westin SN, Broaddus R, Lu K. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. Cancer, 2013. e-Pub 2013. PMID: 23760948.
89. Sailors MH, Bodurka DC, Gning I, Ramondetta LM, Williams LA, Mendoza TR, Agarwal S, Sun CC, Cleeland CS. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol, 2013. e-Pub 2013. PMID: 23685012.
90. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study. Cancer, 2013. e-Pub 2013. PMID: 22072418.
91. Eberth JM, Prarelkar P, Nguyen H, Sun C, Irvin-Vidrine J, Elting LS. The Human and Economic Burden of Cervical Cancer in Texas. Tex Public Health J 65(2):51-55, 2013. e-Pub 2013. PMID: 24466566.
92. Noguera IR, Sun CC, Broaddus RR, Branham D, Levenback CF, Ramirez PT, Sood AK, Coleman RL, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Gynecol Oncol 125(3):640-5, 2012. e-Pub 2012. PMID: 22387451.
93. Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, Schmeler K, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 125(3):661-6, 2012. e-Pub 2012. PMID: 22406638.
94. Worley MJ, Anwandter C, Sun CC, dos Reis R, Nick AM, Frumovitz M, Soliman PT, Schmeler KM, Levenback CF, Munsell MF, Ramirez PT. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol 125(1):241-4, 2012. e-Pub 2012. PMID: 22240566.
95. Frumovitz M, Kriseman ML, Sun CC, Blumenthal-Barby J, Sood AK, Bodurka DC, Soliman PT. Unverifiable Accomplishments and Publications on Applications for Gynecologic Oncology Fellowships. Obstet Gynecol 119(3):504-8, 2012. e-Pub 2012. PMID: 22353948.
96. Ramondetta LM, Urbauer D, Brown AJ, Richardson G, Thaker PH, Koenig HG, Levenback C, Sun CC. Work related stress among gynecologic oncologists. Gynecol Oncol 123(2):365-9, 2011. e-Pub 2011. PMID: 21777966.
97. Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, Westin SN, Brown J, Levenback CF, Ramirez PT. Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol 123(2):333-6, 2011. e-Pub 2011. PMID: 21872911.
98. Schlumbrecht MP, Sun CC, Wong KN, Broaddus RR, Gershenson DM, Bodurka DC. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer 117(16):3741-9, 2011. e-Pub 2011. PMID: 21319148.
99. Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer, 2011. e-Pub 2011. PMID: 21192063.
100. Schmeler KM, Sun CC, Malpica A, Deavers MT, Bodurka DC, Gershenson DM. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol 121(3):482-6, 2011. e-Pub 2011. PMID: 21397305.
101. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, Brown J, Gano JB, Burke TW, Ramondetta LM. A Phase II Trial of Paclitaxel and Carboplatin in Women with Advanced or Recurrent Uterine Carcinosarcoma. Int J Gynecol Cancer 21(3):517-22, 2011. e-Pub 2011. PMID: 21436700.
102. Ramondetta L, Brown A, Richardson G, Urbauer D, Thaker PH, Koenig HG, Gano JB, Sun C. Religious and Spiritual Beliefs of Gynecologic Oncologists May Influence Medical Decision Making. Int J Gynecol Cancer 21(3):573-81, 2011. e-Pub 2011. PMID: 21436706.
103. Schlumbrecht MP, Gallagher CM, Sun CC, Ramondetta LM, Bodurka DC. Ethics Consultation on a Gynecologic Oncology Service: An Opportunity for Physician Education. J Cancer Educ 26(1):183-7, 2011. e-Pub 2011. PMID: 20835927.
104. Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, Bodurka DC, Gershenson DM, Crawford J, Lu KH. Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary. Gynecol Oncol 120(2):229-32, 2011. e-Pub 2011. PMID: 21126756.
105. Agarwal S, Schmeler KM, Ramirez PT, Sun CC, Nick A, Dos Reis R, Brown J, Frumovitz M. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histologic subtypes. Int J Gynecol Cancer 21(1):123-7, 2011. e-Pub 2011. PMID: 21178574.
106. Frumovitz M, Etchepareborda M, Sun CC, Soliman PT, Eifel PJ, Levenback CF, Ramirez PT. Primary malignant melanoma of the vagina. Obstet Gynecol 116(6):1358-65, 2010. e-Pub 2010. PMID: 21099603.
107. Wong KK, Tsang YTM, Deavers MT, Mok SC, Zu Z, Sun CC, Malpica A, Wolf JK, Lu KH, Gershenson DM. BRAF Mutation is rare in Advanced Stage Low-Grade Ovarian Serous Carcinomas. The American Journal of Pathology 177(4):1611-7, 2010. e-Pub 2010. PMID: 20802181.
108. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors. J Clin Oncol 28(27):4214-20, 2010. e-Pub 2010. PMID: 20733129.
109. Brandt AC, Tschirgi ML, Ready KJ, Sun CC, Darilek S, Hecht J, Arun BK, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-87, 2010. e-Pub 2010. PMID: 20431955.
110. Ready KJ, Daniels MS, Sun CC Peterson SK, Northrup H, Lu KH. Obstetrics/Gynecology Residents' Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. J Cancer Educ Epub ahead of print(3):401-4, 2010. e-Pub 2010. PMID: 20186516.
111. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol 116(2 Pt 1):269-73, 2010. e-Pub 2010. PMID: 20664385.
112. Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol Epub ahead of print(4):675-82, 2010. e-Pub 2010. PMID: 19841329.
113. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: implications for Survivors. Cancer 116(3):625-30, 2010. e-Pub 2010. PMID: 20052724.
114. Tung CS, Sun CC, Schlumbrecht MP, Meyer LA, Bodurka DC. Survival after intestinal perforation: can it be predicted?. Gynecol Oncol 115(3):349-53, 2009. e-Pub 2009. PMID: 19765809.
115. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 2009. e-Pub 2009. PMID: 19361839.
116. Frumovitz M, Sun CC, Schmeler KM, Deavers MT, Dos Reis R, Levenback CF, Ramirez PT. Parametrial Involvement in Radical Hysterectomy Specimens for Women With Early-Stage Cervical Cancer. Obstet Gynecol 114(1):93-99, 2009. e-Pub 2009. PMID: 19546764.
117. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 115(9):1867-74, 2009. e-Pub 2009. PMID: 19241422.
118. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-47, 2009. e-Pub 2009. PMID: 19194760.
119. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 2009. e-Pub 2009. PMID: 19280625.
120. Frumovitz M, Sun CC, Jhingran A, Schmeler KM, Dos Reis R, Milam MR, Soliman PT, Taylor K, Ramirez PT. Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol 112(4):899-905, 2008. e-Pub 2008. PMID: 18827134.
121. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int Joun of Gyn Can 18(4):660-669, 2008. e-Pub 2008. PMID: 17892451.
122. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 2008. e-Pub 2008. PMID: 18640930.
123. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-95, 2008. e-Pub 2008. PMID: 18640929.
124. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113(2):326-35, 2008. e-Pub 2008. PMID: 18506736.
125. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-46; discussion 846-8, 2008. e-Pub 2008. PMID: 18471707.
126. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-4, 2008. e-Pub 2008. PMID: 18155273.
127. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol 111(3):747-51, 2008. e-Pub 2008. PMID: 18310380.
128. Jones KL, Saucier JM, Sun CC, Bevers MW, Ramondetta LM, Brown J, Smith JA. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract 14(1):31-6, 2008. e-Pub 2008. PMID: 18337438.
129. Du XL, Sun CC, Milam MR, Bodurka DC, Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. International Journal of Gynecological Cancer 18(4):660-669, 2008. e-Pub 2008. PMID: 17892451.
130. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158-64, 2007. e-Pub 2007. PMID: 17925543.
131. Frumovitz M, dos Reis R, Sun CC, Milam MR, Bevers MW, Brown J, Slomovitz BM, Ramirez PT. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol 110(1):96-102, 2007. e-Pub 2007. PMID: 17601902.
132. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1):52-60, 2007. e-Pub 2007. PMID: 17592291.
133. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105(3):625-9, 2007. e-Pub 2007. PMID: 17320156.
134. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8, 2007. e-Pub 2007. PMID: 17292461.
135. Tseng JF, Pisters PW, Lee JE, Wang H, Gomez HF, Sun CC, Evans DB. The learning curve in pancreatic surgery. Surgery 141(5):694-701, 2007. e-Pub 2007. PMID: 17511115.
136. dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecologic Oncology 107(3):458-463, 2007. e-Pub 2007. PMID: 17854872.
137. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, Lu KH, Bodurka DC. Are women ready for the HPV vaccine?. Gynecol Oncol 103(1):151-4, 2006. e-Pub 2006. PMID: 16551476.
138. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson DM. A Phase II trial of oral capecitabine in patients with platinum - and taxane - refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 102(3):468-74, 2006. e-Pub 2006. PMID: 16516276.
139. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 2006. e-Pub 2006. PMID: 16946209.
140. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK Tyrosine Kinase is Expressed in High-Grade Serous Carcinoma of the Ovary. Cancer Biol Ther 5(9):1136-41, 2006. e-Pub 2006. PMID: 16855388.
141. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108(2):361-8, 2006. e-Pub 2006. PMID: 16880307.
142. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun CC, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106(11):2452-8, 2006. e-Pub 2006. PMID: 16639738.
143. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261-9, 2006. e-Pub 2006. PMID: 16421367.
144. Zighelboim I, Ramirez PT, Gao F, Slomovitz BM, Sun CC, Frumovitz M, Jhingran A, Levenback C. Retroperitoneal lymph node resection in patients with cervical cancer. Surgical Oncology 15(2):79-83, 2006. e-Pub 2006.
145. Ramondetta LM, Sun CC, Hollier L, Jarrett L, Folloder J, Tortolero-Luna G, Hughes A, Brown J. Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecologic Oncology 103(2):547-553, 2006. e-Pub 2006.
146. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 99(2):388-92, 2005. e-Pub 2005. PMID: 16051336.
147. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428-36, 2005. e-Pub 2005. PMID: 16234510.
148. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer 15(4):646-56, 2005. e-Pub 2005. PMID: 16014119.
149. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-27, 2005. e-Pub 2005. PMID: 15538640.
150. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105(3):575-80, 2005. e-Pub 2005. PMID: 15738027.
151. Ramondetta LM, Jenkins AD, Sun CC, Johnston T, Wolf JK, Bodurka DC, Brown J, Atkinson EN, Levenback C. Phase II Trial of Capecitabine in Recurrent Squamous Cell Carcinoma of the Cervix. Gynecol Oncol 97(3):840-844, 2005. e-Pub 2005. PMID: 15882895.
152. Ramirez PT, Sun CC, Vidal CI, Schimp V, Slomovitz BM, Bevers MW, Bodurka DC. Outcomes of hysteroscopy and hysterectomy in breast cancer patients. Cancer Therapy:in press, 2005. e-Pub 2005.
153. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Sun CC, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic Malignancy as a “Sentinel Cancer” for Women with HNPCC. Obstetrics & Gynecology 105(3):569-74, 2005. e-Pub 2005.
154. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8(8):935-49; discussion 949-50, 2004. e-Pub 2004. PMID: 15585381.
155. Tseng JF, Kronowitz SJ, Sun CC, Perry AC, Hunt KK, Babiera GV, Newman LA, Singletary SE, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 101(7):1514-23, 2004. e-Pub 2004. PMID: 15378473.
156. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 199(3):388-93, 2004. e-Pub 2004. PMID: 15325608.
157. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. Obstet Gynecol 104(2):255-60, 2004. e-Pub 2004. PMID: 15291996.
158. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94(2):456-62, 2004. e-Pub 2004. PMID: 15297188.
159. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22(15):3126-32, 2004. e-Pub 2004. PMID: 15284264.
160. Smith JA, Kindo CC, Kurian S, Whitaker LM, Burke C, Wachel B, Sun CC, Weaver CL, Danielson MG, Fitzgerald MA, Munsell M, Zandstra FA, Bodurka DC. Evaluation of patient chemotherapy education in a gynecology oncology center. Support Care Cancer 12(8):577-83, 2004. e-Pub 2004. PMID: 15168104.
161. Schimp VL, Worley C, Brunello S, Levenback CC, Wolf JK, Sun CC, Bodurka DC, Ramirez PT. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol 92(2):586-91, 2004. e-Pub 2004. PMID: 14766251.
162. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun CC, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4):758-64, 2003. e-Pub 2003. PMID: 12910520.
163. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. Gynecol Oncol 87(1):118-28, 2002. e-Pub 2002. PMID: 12468352.
164. Robinson JB, Sun CC, Bodurka-Bevers D, Im DD, Rosenshein NB. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol 78(2):235-41, 2000. e-Pub 2000. PMID: 10926809.
165. Cantor SB, Sun CC, Tortolero-Luna G, Richards-Kortum R, Follen M. A comparison of C/B ratios from studies using receiver operating characteristic curve analysis. J Clin Epidemiol 52(9):885-92, 1999. e-Pub 1999. PMID: 10529029.
166. Cantor SB, Mitchell MF, Tortolero-Luna G, Bratka CS, Bodurka DC, Richards-Kortum R. Cost-effectiveness analysis of diagnosis and management of cervical squamous intraepithelial lesions. Obstet Gynecol 91(2):270-7, 1998. e-Pub 1998. PMID: 9469288.

Invited Articles

1. Meyer L, Suidan R, Sun CC, Westin S, Coleman RL, Mills GB. The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. Expert Rev Qual Life Cancer Care 1(3):231-238, 2016. e-Pub 2016. PMID: 30906877.
2. Bodurka DC, Huang M, Sun CC. Caring for Cancer Patients in the Future: A Perfect Storm on the Horizon?. Oncology (Williston Park) 24(14):1351-2, 2010. e-Pub 2010. PMID: 21294483.
3. Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18-29, 2007. e-Pub 2007. PMID: 17183353.
4. Bodurka DC, Sun CC, Gerhsenson DM. Review on, "Reproductive issues in the gynecologic cancer patient" Carter J, et al. Oncology 21(5):598-609, 2007. e-Pub 2007.
5. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am 33(4):621-630, 2006. e-Pub 2006. PMID: 17116505.
6. Sun CC, Frumovitz M, Bodurka DC. Quality of life and gynecologic malignancies. Curr Oncol Rep 7(6):459-65, 2005. e-Pub 2005. PMID: 16221383.
7. Bodurka-Bevers D, Sun CC, Gershenson DM. Economic issues related to ovarian cancer. Oncology Economics 1(9):40-47, 2000. e-Pub 2000.

Review Articles

1. Meyer, LA, Schneider, A, Aghajani, H, Basabe, M, Martinez, LH, Estrada, GM, Iniesta-Donate, M, Liao, Y, Sun, CC. Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer. Journal of Clinical Oncology 42:5574, 2024. e-Pub 2024.
2. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol 156(3):715-725, 2020. e-Pub 2020. PMID: 31969252.
3. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95(1):133-8, 2004. e-Pub 2004. PMID: 15385122.
4. Bodurka-Bevers D, Sun CC, Gershenson DM. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics 17(2):133-50, 2000. e-Pub 2000. PMID: 10947337.

Professional Educational Materials

1. Sun CC. Ovarian Cancer: Quality of Life Issues, National Ovarian Cancer Coalition, 2005.
2. Sun CC. Helping Cancer Patients with Quality of Life Treatment Decisions, 2005.

Other Articles

1. Huepenbecker S, Fu S, Sun CC, Zhao H, Primm K, Giordano SH, Meyer LA Medicaid Expansion and 2-Year Survival in Women With Gynecologic Cancer. Obstetrical and Gynecological Survey 77(12):737-738, 2022.

Editorials

1. Gershenson, DM, Burns, K, Sun, CC. Update on contemporary treatment for newly diagnosed stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC). Gynecologic oncology 202:85-86, 2025. PMID: 41033228.
2. Bodurka DC, Sun CC, Frumovitz MMF. Quality of life in cervix cancer survivors – What matters the most in the long-term?. Gynecologic Oncology 97:307-309, 2005.

Abstracts

1. Adjei NN, Schneider AK, Westin SN, Sun CC, Meyer LA. Combating the financial burden of ovarian cancer: It takes a village. Gyn Oncol, 2023. e-Pub 2023.
2. Adjei NN, Haas A, Zhao H, Primm KM, Sun CC, Meyer LA. Trends in the use of maintenance therapy in ovarian cancer. ASCO, 2023. e-Pub 2023.
3. Sun CC, Schneider A, Huepenbecher S, et al. Hope and choices: direct patient preference elicitation for durable versus fixed survival gains in women with recurrent ovarian cancer (ROC). IJGC 32:A170 - 171, 2022. e-Pub 2022.
4. Meyer L, Sol Basabe M, Schneider A, Westin S, Lowenstein L, Volk R, Sun C. Side effects and decision-making factors associated with maintenance therapy: patient preferences using a visual scale analog (VAS) assessment. IJGC 32:A159-A160, 2022. e-Pub 2022.
5. Sun C, Schneider A, Sol Basabe M, Westin S, Lowenstein L, Volk R. Do patients prefer maintenance therapy or surveillance? Weighing gain in progression-free survival and risks of adverse events via time trade-off and standard gamble assessments. International Journal of Gynecologic Cancer 2022;32:A171-A172. IJGC 32:A171-A172, 2022. e-Pub 2022.
6. Meyer LA, Sun CC, Lowenstein LM, Leal VB, Crocker LC, Basabe S, Schneider AK, Iniesta M, Westin SN, Volk RJ. Ovarian cancer patients’ knowledge of advanced ovarian cancer and maintenance therapy: Differences across disease and maintenance therapy status. Gyn Oncol 166(Suppl 1):S234, 2022. e-Pub 2022.
7. Huepenbecker S, Deshmukh AA, Sun C, Rajan SS, Harrison R, Giordano S, Meyer L. Cost-utility analysis of management strategies after frontline treatment of women with advanced epithelial ovarian cancer. Gyn Oncol 166(Suppl 1):S174 -S175, 2022. e-Pub 2022.
8. Heupenbecker S, Sun CC, Fu S, Zhao H, Primm K, Giordano L, Meyer L. Impact of Medicaid expansion on postoperative mortality in women with gynecologic cancer: a difference-in-difference analysis. Gyn Oncol 166(Suppl 1):S16, 2022. e-Pub 2022.
9. Zhang Y, Sun CC Cobb LP, Westin SN, Gershenson DM. The Clinical Course of Women Who Undergo Contemporary Management of Stage ll-lV Low-Grade Serous Carcinoma of the Ovary/Peritoneum (LGSOC). Gyn Oncol 166(Suppl 1):S257 - S258, 2022. e-Pub 2022.
10. Meyer LA, Lowenstein L, Sun CC, Leal V, Crocker LC, Basabe S, Alexander JD, Schneider A, Westin SN, Volk RJ. Knowledge Measure for Ovarian Cancer Research (KnoMOR): Development and psychometric testing results of a patient-centered knowledge measure. Gyn Oncol 166 Supplement:S21, 2022. e-Pub 2022.
11. Gibbons-Sidey C, Sun CC, Cai X, Schneider A, Lu S, Subbiah IM, Wright AA, Meyer L. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data. J Clin Oncol Suppl 15(39):15, 2021. e-Pub 2021.
12. Primm K, Heupenbecker S, Zhao H, Sun C, Fu S, Meyer L, Hernandez D, Chang S. Exploring Racial and Ethnic Differences in Time to Treatment for Breast, Colorectal, and Lung Cancer: A National Cancer Database Study. National Camcer Database, 2021. e-Pub 2021.
13. Basabe S, Sun CC, Volk RJ, Lowenstein L, Schneider A, Leal VB, Crocker LC, Alexander JD, Iniesta M, Meyer LA. Knowledge about advanced ovarian cancer and maintenance therapy: Does experience matter?. IJGC 257(31):A102-A103, 2021. e-Pub 2021.
14. Huepenbecker S, Fu S, Zhao H, Primm K, Sun C, Giordano S, Meyer L. Temporal trends of healthcare system costs and utilization related to ovarian cancer diagnosis in the United States. IJGC 260(31):A104, 2021. e-Pub 2021.
15. Huepenbecker S, Fu S, Zhao H, Primm K, Sun C, Rauh-Hain A, Giordano S, Meyer L. Do factors affecting time from symptom onset to diagnosis or treatment of ovarian cancer also affect survival?. Gyn Oncol 162(Suppl 1):S140, 2021. e-Pub 2021.
16. Huepenbecker S, Fu S, Zhao H, Primm K, Sun C, Giordano S, Meyer L. Factors affecting time from symptom onset to ovarian cancer diagnosis in the United States. Gyn Oncol 162:S158 -159, 2021. e-Pub 2021.
17. Meyer L, Schneider AK, Molina E, Villanueva M, Lowenstein LM, Williams LA, Sun CC. A qualitative exploration of the impact of ovarian cancer on the well-being of women: evaluating the intersection and influences of social determinants of health. Gyn Oncol 162(Suppl 1):S78 - S79, 2021. e-Pub 2021.
18. Mulder I, Flemin N, Sun C, Fellman B, Ulin L, Ozer M, Coleman R, Ramirez P, Rangel K, Soliman P, Nick A, Lu K, Sood A, Westin S. Impact of a Laparoscopic Triage Program for Advanced Ovarian Cancer on Surgical Outcomes, Disease-free Survival, and Overall Survival. IGCS Journal 30(A165):344, 2020. e-Pub 2020.
19. Harrison R, Zhao H, Fu S, Sun CC, Westin W, Lu KH, Giordano S, Meyer LA. Is an endometrial cancer diagnosis a “teachable moment” leading to weight loss among obese 3 women? A case-control study. Gyn Oncol, 2020. e-Pub 2020.
20. Sun CC, Molina E, Schneider A, Harrison RF, Westin SN, Coleman RL, Lowenstein LM, Volk RJ, Meyer LA. Patient preferences for side effects and decision-making factors associated with maintenance therapy for ovarian cancer. Gyn Oncol 159(Suppl 1):75, 2020. e-Pub 2020.
21. Villanueva M, Sun CC, Schneider A, Molina E, Shi Q, Wang S, Meyer LA. Exploring the utility and burden of clinical follow up of threshold alerts generated by patient-reported outcomes in women with recurrent ovarian cancer: A longitudinal study. Gyn Oncol 159(Suppl 1):272, 2020. e-Pub 2020.
22. Meyer L, Schneider AK, Molina E, Villaneuva M, Lowenstein LM, Williams LA, Sun CC. More toxic than treatment? The financial impact of living with ovarian cancer: A qualitative exploration of financial toxicity in women with recurrent ovarian cancer. Gyn Oncol 159(Suppl 1):85 - 86, 2020. e-Pub 2020.
23. Harrison RF, Fu S, Sun CC, Zhao H, Lu KH, Giordano SH, Meyer L. Out-of-pocket costs for PARP inhibitor treatment: Are ovarian cancer patients at risk for financial toxicity?. Gyn Oncol 159(Suppl 1):21, 2020. e-Pub 2020.
24. Sun CC, Molina E, Schneider A, Harrison RF, Westin SN, Coleman RL, Lowenstein LM, Volk RJ, Meyer LA. Patient preferences for maintenance therapy vs. routine surveillance: Gain in progression-free survival and risks of adverse effects. Gyn Oncol 159(Suppl 1):75-76, 2020. e-Pub 2020.
25. Harrison R, Noer MC, Hogdall C, Fu S, Zhao H, Sun CC, Lu KH, Giordano S, Meyer LA. Secondary validation of an ovarian cancer-specific comorbidity index in a US population. Gyn Oncol 159(Suppl 1):100, 2020. e-Pub 2020.
26. Harrison R, He W, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, Meyer LA. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or hyperplasia with atypia,. Gyn Oncol 27(154 (Supp 1)):18-19, 2019. e-Pub 2019.
27. Armbruster SD, Sun CC, Song J, Gatus L, Lu KH, Basen-Engquist KM. Endometrial cancer survivors one decade post-exercise intervention: Happier and healthier?. Gyn Oncol 154(154 Supp; 1):20-21, 2019. e-Pub 2019.
28. Lowenstein LM, Sun CC, Leal VB, Crocker L, Savelieva K, Westin SN, Coleman RL, Volk RJ, Meyer LA. Decision making about maintenance therapy for ovarian cancer: qualitative exploration of factors important to patients/caregivers and clinicians. ISDM, 2019. e-Pub 2019.
29. Harrison R, Cantor SB, Sun CC, Villanueva M, Stewart KI, Woodard TL, Shafer A, Lu KH, Meyer LA. “What is the opportunity cost of postmolar surveillance for women of advanced maternal age seeking pregnancy? A Monte Carlo microsimulation model.”. Gyn Oncol 154(Suppl 1):196-107, 2019. e-Pub 2019.
30. Meyer LA, Shi Q, Schneider AK, Lin HK, Molina E, Williams L, Savelieva K, Soliman PT, Westin SN, Wang XS, Sun CC. Symptom trajectory in women with recurrent ovarian cancer: How does symptom burden change near the end of life?. Gyn Oncol 154(Suppl 1):160, 2019. e-Pub 2019.
31. Meyer L, Sun C, Savelieva K, Leal VB, Crocker LC, Molina E, Westin S, Coleman RL, Volk RJ, Lowenstein LM. Patient decision-making regarding maintenance therapy for ovarian cancer: A qualitative exploration. Gyn Oncol 154(Suppl 1):25 - 26, 2019. e-Pub 2019.
32. Suidan RS, Sun CC, Lu KH, Giordano SH, Meyer LA. Prospective assessment of patient preferences in ovarian cancer: what do patients value the most?. Gyn Oncol 154(Suppl 1):161, 2019. e-Pub 2019.
33. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Sood AK, Wong KK, Silva EG, Gershenson DM. “The role of neoadjuvant chemotherapy in the management of low grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.”. Gyn Oncol 154(Suppl 1):241-242, 2019. e-Pub 2019.
34. Suidan RS, Sun CC, Cantor SB, Frumovitz M, Giordano SH, Meyer LA. A cost-utility analysis of sentinel lymph node mapping vs complete lymphadenectomy in the management of early-stage cervical carcinoma. Gyn Oncol 154(Suppl 1):191, 2019. e-Pub 2019.
35. Harrison R, Zhao H, He W, Sun CC, Suidan RS, Armbruster S, Rauh-Hain JA, Lu KH, Giordano SH, Meyer LA. “Body mass index and intention for health behavior change before and after treatment of endometrial cancer.”. Gyn Oncol 154(Suppl 1):2226, 2019. e-Pub 2019.
36. Meyer LA, Sun CC, Shi Q, Weestin SN, Haq S, Savelieva K, Coleman RL, Mills GB, Williams LA. Longitudinal patient-reported outcomes (PROs) and qualitative assessment of symptom burden within a phase 1b trial of a PARP inhibitor olaparib combined with an oral mTORC1/2 inhibitor (AZD2014) or an AKT inhibitor (AZD5363). Quql Life Res 27(Suppl 1):1121, 2018. e-Pub 2018.
37. Williams LA, Sun CC, Haq S, Savelieva K, Shi Q, Coleman RL, Westin SN, Mills GB, Meyer LA. Use of qualitative interviews in a developmental therapeutic clinical trial to guide refinement of content domain within an existing PRO instrument. Qual Life Res 27 (Suppl1):559 27(Suppl 1):1017, 2018. e-Pub 2018.
38. Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. Perirenal adiposity is associated with lower progression-free survival from ovarian cancer. Int J Gynecol Cancer 28(2):285-292, 2018. e-Pub 2018. PMID: 29303933.
39. Matsuo K, Wong KK, Fotopoulou C, Blake EA, Robertson SE, Pejovic T, Frimer M, Pardeshi V, Hu W, Choi JS, Sun CC, Richmond AM, Marcus JZ, Hilliard MAM, Mostofizadeh S, Mhawech-Fauceglia P, Abdulfatah E, Post MD, Saglam O, Shahzad MMK, Karabakhtsian RG, Ali-Fehmi R, Gabra H, Roman LD, Sood AK, Gershenson DM. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. J Surg Oncol 117(2):236-244, 2018. e-Pub 2018. PMID: 28787528.
40. Meyer L, Shi Q, Iniesta M, Harris M, Sun CC, Lasala J. Comparison of patient reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. J Clinical Oncology 35(No 15 (Suppl May)):5557-5557, 2017. e-Pub 2017.
41. Suidan RS, He W, Sun CC, Zhao H, Lu KH, Giordano SH. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. J Clinical Oncology 35(No 15 (Suppl May)):6602-6602, 2017. e-Pub 2017.
42. Meyer LA, Nick AM, Shi Q, Iniesta MD, Lasala JD, Harris M, Sun CC, Lu KH, Ramirez PT. Comparison of longitudinal patient reported outcomes on an enhanced recovery pathway in patients with ovarian cancer undergoing primary vs interval cytoreductive surgery. Gynecologic Oncology 145(Suppl 1):207-208, 2017. e-Pub 2017.
43. Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, Lu KH, Giordano SH, Meyer LA. . National trends, outcomes and costs of radiation therapy in the management of low-and high-intermediate risk endometrial cancer. Gynecologic Oncology 145(Suppl 1):133-134, 2017. e-Pub 2017.
44. Shah JS, Bodurka DC, Sun CC, Chisholm G, Woodard TL. Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of SGO members. Gynecologic Oncology 145(Suppl 1):175-176, 2017. e-Pub 2017.
45. Brown AJ, Shen MJ, Urbauer D, Taylor JS, Parker PA, Carmack C, Prescott LS, Sun CC, Ramondetta LM, Bodurka DC. Room for Improvement: An Examination of Advance Care Planning Documentation Among Gynecologic Oncology Patients. Accepted for oral plenary presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
46. Suidan RS, Hu W, Sun CC, Zao H, Giordano S, Meyer LA. Treatment patterns and outcomes for bowel obstruction in elderly ovarian cancer patients: A population-based analysis. Accepted for poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
47. Meyer LA, He W, Sun CC, Zhao H, Suidan RS, Lu KH, Giordiano SH. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: a population based analysis. Accepted for a poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer, 2016. e-Pub 2016.
48. Meyer L, Suidan R, He W, Sun CC, Zhao H, Westin S, Soliman P, Woodard T, Lu K, Giordano S. Endometrial hyperplasia and cancer in young women: A study of national patterns of care over time and pregnancy outcomes. 16th Biennial Meeting of the International Gynecologic Cancer Society, 2016. e-Pub 2016.
49. Suidan RS, He W, Sun CC, Soliman PT, Ramirez PT, Zhao H, Fleming ND, Westin SN, Lu KH, Giordano SH, Meyer LA. Impact of body mass index on surgical costs and morbidity for women with endometrial carcinoma/hyperplasia. J Clin Oncol 34, 2016. e-Pub 2016.
50. Armbruster SD, Sun CC, Soliman PT, Westin SN, Bodurka DC, Ramondetta LM, Bradford AM, Basen-Engquist K. Prospective assessment of patient perception and quality of life in gynecologic patients after pelvic exenteration. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
51. Nebgen DR, Holman LL, Hurteau J, Keeler E, Chisholm GB, Sun CC, Lu KH. Prophylactic salpingectomy with delayed oophorectomy (PSDO): Feasibility study in women with BRCA mutations. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
52. Bednar EM, Oakley HD, Sun CC, Westin SN, Lu KH. Universal Germline BRCA Testing of Ovarian Cancer Patients and Implications for Treatment. Accepted for a Poster presentation at the American Society of Clinical Oncology Annual Meeting, J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
53. Soliman PT, Nick AM, Sun CC, Dioun SM, Pal N, Frumovitz M, Ramirez SV, Lu KH, Westin SN. Obesity significantly reduces the sentinel lymph node detection rate in women with endometrial cancer. Accepted for featured poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer 141(Suppl 1):31, 2016. e-Pub 2016.
54. Bednar EM, Oakley HD, Sun CC, Daniels MS, Rayes N, Yates M, Nick AM, Mills GB, Gonzalez-Rosa K, Lu KH. Achieving universal BRCA1 and BRCA2 genetic testing with a novel care delivery model. Accepted for poster presentation at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer 141(Suppl 1):80, 2016. e-Pub 2016.
55. Westin SN, Sun CC, Broaddus R, Pal N, Woodall M, Urbauer D, Ramondetta LM, Lu KH, Coleman RL, Bodurka DC. Challenging the paradigm of progesterone-only therapy for early endometrial cancer: Results of a prospective trial of the levonorgestrel intrauterine system. Accepted for an oral presentation (focused plenary) at the Society for Gynecologic Oncology 47th Annual Meeting on Women’s Cancer 141(Suppl 1):18-19, 2016. e-Pub 2016.
56. Brown AJ, Shen MJ, Urbauer D, Taylor JS, Parker PA, Carmack C, Prescott LS, Sun CC, Ramondetta LM, Bodurka DC. The Advance Care Planning Readiness Scale: A Novel Measure of Gynecologic Oncology Patients’ Willingness to Discuss and to Accept End of Life Care. Accepted for poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women’s Cancer 141(Suppl 1):79-80, 2016. e-Pub 2016.
57. Taylor JS, Marten C, Sun CC, Bodurka D, Potts K, Nick A, Meyer L, Levenback C, Lairson D, Schmeler K. The cost-effectiveness of the DISINFECT Initiative (Decreasing the Incidence of Surgical INFECTions) in Gynecologic Oncology. Accepted for poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer 141(Suppl 1):87, 2016. e-Pub 2016.
58. Prescott LS, Vergote IB, Coens C, Sun CC, Munsell MF, Casado A, Coleman RL, Bodurka DC. Effect of perioperative blood transfusion on quality of life, progression-free and overall survival in primary treatment of advanced epithelial ovarian cancer: An EORTC ancillary study. Gynecologic Oncology: Accepted for poster presentation at the Society for Gynecologic Oncology 47th Annual Meeting on Women's Cancer 141(Suppl 1):198, 2016. e-Pub 2016.
59. Meyer LA, He W, Sun CC, Zhao H, Suidan RS, Lu KH, Giordano SH, Bodurka DC. Uptake and outcomes associated with neoadjuvant chemotherapy in the elderly: A population-based analysis. Gynecologic Oncology 141(Suppl 1):169, 2016. e-Pub 2016.
60. Suidan RS, He W, Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, Lu KH, Giordano SH, Meyer LA. Treatment patterns and outcomes for bowel obstruction in elderly ovarian cancer patients: A population-based analysis. Gynecologic Oncology 141(Suppl 1):131, 2016. e-Pub 2016.
61. Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal maintenance therapy for women with low grade serous carcinoma of the ovary or peritoneum. J Clin Oncol 34(Suppl), 2016. e-Pub 2016.
62. Zhang Y, Allen P, Meyer LA, Sun CC, Basen-Engquist KM, Lu KH, Klopp AH. Visceral adiposity associated with increased risk of death from ovarian cancer. Gynecologic Oncology 137(Suppl 1):118, 2015. e-Pub 2015.
63. Meyer LA, He W, Zhao H, Sun CC, Wright A, Bodurka DC, Lu KH, Giordano SH. Patterns of care and survival in a matched case-control study of intraperitoneal chemotherapy in a national population-based cohort of elderly ovarian cancer patients. Gynecologic Oncology 137(Suppl 1):175-176, 2015. e-Pub 2015.
64. Ramondetta LM, Kim YJ, Munsell MF, Park J, Meyer LA, Sun CC, Brown AJ, Bodurka DC, Bruera E. Symptom burden in women with advanced or recurrent cervical cancer referred to a supportive care center. Gynecologic Oncology 137(Suppl 1):197, 2015. e-Pub 2015.
65. Taylor JS, Brown AJ, Prescott LS, Sun CC, Ramondetta LM, Bodurka DC. How equal is end of life care among gynecologic oncology patients?. Gynecologic Oncology 137(Suppl 1):194-195, 2015. e-Pub 2015.
66. O’Malley DM, Niland J, Bookman MA, Burger RA, Cristea M, Griggs J, Mantea-Smaldone GM, Meyer LA, Sun CC, Wright A, Cohn DE. The use of NCCN guideline therapy in the first line/adjuvant setting in patients with ovarian cancer from 6 NCCN Institutions. Gynecologic Oncology 137(Suppl 1):42, 2015. e-Pub 2015.
67. Soliman PT, Westin SN, Sun CC, Dioun S, Frumovitz M, Nick AM, Fleming ND, Ramirez PT, Levenback CF, Lu KH. Sentinel lymph node mapping accurately identifies positive nodes in women with high risk endometrial cance. Gynecologic Oncology 138(Suppl 1):3, 2015. e-Pub 2015.
68. Prescott LS, Quinn D, Sun CC, Soliman PT, Schmeler KM, Levenback C, Watkins J, Garcia E, Urbauer D, Bodurka DC. Fighting Cancer Together: Shared Medical Appointments - A Feasibility Survey. Accepted for poster presentation at the Society of Gynecologic Oncology 45th Annual Meeting, 2014. e-Pub 2014.
69. Frumovitz MM, Ramondetta LM, Sun CC, Jhingran A, Fleming ND, Schmeler KM, Ramirez PT. Laparoscopic Extraperitoneal Paraaortic Lymph Node Dissection: You Too Can Do It!. Accepted for poster presentation at the Society of Gynecologic Oncology 45th Annual Meeting, 2014. e-Pub 2014.
70. Brown AJ, Sun CC, Prescott LS, Ramondetta LM, Bodurka DC. Missed Opportunities: Patterns of Medical Care and Hospice Utilization Among Ovarian Cancer Patient. Accepted for poster presentation at the Society of Gynecologic Oncology 45th Annual Meeting, 2014. e-Pub 2014.
71. Brown AJ, Sun CC, Prescott LS, Ramondetta LM, Bodurka DC. An Afterthought: End-of-life care documentation among ovarian cancer patients. Accepted for poster presentation at the Society of Gynecologic Oncology 45th Annual Meeting, 2014. e-Pub 2014.
72. King ER, Sun CC, Ramirez PT, Schmeler KM, Malpica A, Gershenson DM. The role of secondary cytoreduction in patients with recurrent low-grade serous ovarian carcinoma. Poster presentation at the Society of Gynecologic Oncology 45th Annual Meeting, 2014. e-Pub 2014.
73. Bruegl AS, Djordjevic B, Rajyalakshmi L, Lu KH, Sun CC, Broaddus R. Cost Analysis Comparing Universal Tumor Testing to Clinical-Based Criteria in Evaluation of Endometrial Adenocarcinomas for Lynch Syndrome. Society of Gynecologic Oncology 45th Annual Meeting -oral presentation, 2014. e-Pub 2014.
74. Solheim O, Gershenson DM, Trope C, Rokkones E, Sun CC, Weedon- Fekjaer H, Fossa S. Prognostic factors in malignant ovarian germ cell tumors: The SEER experience 1978-2010. J Clin Oncol 32(Suppl; abstr e15534), 2014. e-Pub 2014.
75. Meyer L, He W, Zhao W, Sun CC, Buchholz TA, Lu KH, Giordano SH. Patterns of care and overall survival in the Medicare ovarian cancer population. J Clin Oncol 32:5s(Suppl; abstr 5587), 2014. e-Pub 2014.
76. Soliman PT, Sun CC, Westin SN, Ramondetta LM, Bodurka DC, Bradford A. Longitudinal quality of life (QOL) and sexual functioning in women undergoing pelvic exenteration for gynecologic malignancies. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings 31(Supplement 15):5608, 2013. e-Pub 2013.
77. Brown AJ, Huang M, Sun CC, Zaid TM, Balakrishnan N, Mhadgut H, Lu KH, Westin SN, Bodurka DC. Benefits of neoadjuvant chemotherapy in ovarian, primary peritoneal, or fallopian tube carcinoma. Journal of Clinical Oncology - ASCO Annual Meeting Proceedings 31(15 Suppl):5580, 2013. e-Pub 2013.
78. Huang M, Sun CC, Westin SN, Bodurka DC. Hormone replacement therapy (HRT) prescribing patterns among gynecologic oncologists. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 31(15 suppl):e20637, 2013. e-Pub 2013.
79. Westin S, Sun CC, Pal N, Janku F, Tsimberidou A, Falchook G, Hong D, Lu K, Coleman R, Kurzrock R. KRAS mutation in endometrial and ovarian cancers: Preliminary data on association with phenotype and clinical outcome in primary disease. Gynecologic Oncology 130(1):e162, 2012. e-Pub 2012.
80. Holman L, Lu K, Hernandez M, Bast R, Neal S, Skates S, Gershenson D, Sun CC. Changes in perceptions of screening over time among average-risk women undergoing ovarian cancer screening using the risk of ovarian cancer algorithm. Gynecologic Oncology 130(1):e31, 2012. e-Pub 2012.
81. Schlumbrecht M, Milbourne A, Sun CC, Huang M, Bodurka D. Physician preferences for involvement in survivorship care: Are benign gynecologists ready?. Gynecologic Oncology 130(1):e148, 2012. e-Pub 2012.
82. Ramondetta L, Kang Y, Hu W, Sun CC, Kott M, Deavers M, Klopp A, Thaker P, Smith J, Sood A. The clinical significance of beta adrenergic receptor expression in cervical cancer tissue. Gynecologic Oncology 130(1):e54-e55, 2012. e-Pub 2012.
83. Soliman P, Sun CC, Westin S, Fleming N, Schmeler K, Nick A, Ramirez P. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecologic Oncology 130(1):e104, 2012. e-Pub 2012.
84. Westin S, Sun CC, Broaddus R, Pal N, Nath V, Urbauer D, Schmeler K, Lu K, Bodurka D, Johnston T. Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treat complex atypical hyperplasia and grade 1 endometrioid endometrial cancer. Gynecologic Oncology 125(Supplement 1):S9, 2012. e-Pub 2012.
85. Gershenson D, Sun CC, Iyer R, Wong K, Kavanagh J, Malpica A, Schmeler K, Bodurka D, Deavers M. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecologic Oncology 125(Supplement 1):S35, 2012. e-Pub 2012.
86. Sun CC, Jhingran A, Gallegos J, Bodurka D, Frumovitz M, Ramondetta L. Longitudinal quality of life in medically underserved women with locally advanced cervical cancer. Gynecologic Oncology 125(Supplement 1):S50, 2012. e-Pub 2012.
87. Schlumbrecht M, Sun CC, Huang M, Milbourne A, Bodurka D. Survivorship care: Who do gynecologic cancer patients prefer?. Gynecologic Oncology 125(Supplement 1):S76, 2012. e-Pub 2012.
88. Holman L, Lu K, Hernandez M, Bast R, Bodurka D, Skates S, Gershenson D, Sun CC. Perception of risk, cancer worry, anxiety, and acceptability of screening among low-risk women undergoing ovarian cancer screening with the risk of ovarian cancer algorithm. Gynecologic Oncology 125(Supplement 1):S116-117, 2012. e-Pub 2012.
89. Worley M, Anwandter C, dos Reis R, Sun CC, Nick A, Frumovitz M, Soliman P, Schmeler K, Levenback C, Ramirez P. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecologic Oncology 125(Supplement 1):S121, 2012. e-Pub 2012.
90. Pentz RD, Liu Y, Wall L, Daugherty D, Green MJ, Hlubocky FJ, Peterson SK, Sun CC, Dixon M, Harvey RD, Owonikoko TK, Khuri FR. Physicians’ ability to correctly identify values important to cancer patients enrolled in phase I clinical trials. J Clin Oncol 30(Supple; abstr e 13026), 2012. e-Pub 2012.
91. Holman LL, Daniels MS, Brandt AC, Arun B, Keeler E, Gershenson DM, Sun CC, Lu KH. Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation “previvors”. J Clin Oncol 30(suppl; abstr 1518), 2012. e-Pub 2012.
92. Ramondetta LM, Urbauer D, Zhukovsky DS, Bevers MW, Brown J, Bodurka DC, Thaker PH, Anderson S, Gallegos J, Sun CC. Longitudinal study of hope, meaning/peace (M/P), and quality of life (QOL) in patients (pts) with ovarian cancer (OC). J Clin Oncol 30(Suppl; abstr 9134), 2012. e-Pub 2012.
93. Milbourne A, Sun CC, Fanale MA, Theriault RL, Rimes SA, Litton JK, Ramirez MM. Pregnancy outcomes in women with cancer. J Clin Oncol 30(Suppl; abstr 6116), 2012. e-Pub 2012.
94. Huang M, Djordjevic B, Urbauer D, Westin SN, Sun CC, Burzawa JK, Meyer L, Bodurka DC, Broaddus R, Lu KH. Molecular analysis of endometrial pathogenesis in Lynch syndrome. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings 29(15_supplemental):9108, 2011. e-Pub 2011.
95. Pentz RD, Farmer ZL, Green MJ, Daugherty C, Hlubocky FJ, Peterson SK, Sun CC, Lewis CM, Owonikoko TK, Khuri FR, Harvey RD. Assessing patients’ values when standard-of-care options are exhausted. Journal of Clinical Oncology ASCO Annual Meeting Proceedings 29(15_supplement):9108, 2011. e-Pub 2011.
96. Iglesias D, Sun CC, Langstraat C, Bakkum-Gamez J, El-Nashar S, Keeler E, Gershenson D, Lu L. Management and clinical outcomes of women with BRCA1/2 mutations found to have occult cancers at the time of risk-reducing salpingo-oophorectomy. Gynecologic Oncology 120(Supplement 1):S59-S60, 2011. e-Pub 2011.
97. Bodurka DC, Jhingran A, Ramondetta LM, Eifel PJ, Crane CH, Phan AT, Urbauer D, Frumovitz MM, Elting LS, Sun CC. Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). J Clin Oncol 28(15s), 2011. e-Pub 2011.
98. Schlumbrecht MP, Sun CC, Westin SN, Zandstra F, Denton K, Rhodes H, Gonzales DA, Garcia EA, Levenback CL, Bodurka DC. Lifestyle modification in cervical cancer survivors: an ongoing need. Gyncologic Oncology 120(Supplement 1):S109, 2011. e-Pub 2011.
99. Ramondetta LM, Jhingran A, Frumovitz M, Delgado M, Brown J, Eifel P, Palencia J, Sun CC. Protective effects of spirituality and religiosity in underserved women with cervical cancer (CXCA). Support Care Cancer 19(Suppl 2):S67-S370, 2011. e-Pub 2011.
100. Huang M, Westin SN, Sun CC, Meyer L, Tung C, Urbauer D, Bodurka DC. Menopausal Symptoms and Hormone Replacement Use: The Gynecologic Cancer Survivors’ Perspective. Gynecologic Oncology 120(Supplement 1):S59-S60, 2011. e-Pub 2011.
101. Schlumbrecht MP, Sun CC, Wong KN, Broaddus RR, Gershenson DM, Bodurka DC. The Role of Smoking in Low-Grade Serous Ovarian Carcinoma. Gynecologic Oncology 116(Issue 3):S123-S124, 2010. e-Pub 2010.
102. Schlumbrecht MP, Gallagher CM, Sun CC, Ramondetta LM, Bodurka DC. Ethics Consultation on a Gynecologic Oncology Service: A Learning Opportunity for Physicians. Gynecologic Oncology 116(Issue 3):S57-S58, 2010. e-Pub 2010.
103. Daniels MS, Vineyard M, Urbauer D, Deavers M, Sun CC, Boerwinkle E, Bodurka D, Gershenson D, Lu K. Is low grade serous ovarian cancer part of the hereditary breast and ovarian cancer tumor spectrum?. Gynecologic Oncology 116(Issue 3):S98-S99, 2010. e-Pub 2010.
104. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node involvement in primary mucinous carcinoma of the ovary. Gynecologic Oncology 116(Issue 3):S112-S113, 2010. e-Pub 2010.
105. Ramondetta LM, Fields MM, Brown J, Rodriquez S, Folloder J, Sun CC. Barriers to Cervical Cancer Screening in Medically Underserved Women: Still More To Be Done. Gynecologic Oncology 113(Issue 3):S39-S40, 2010. e-Pub 2010.
106. Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistent obesity among endometrial cancer survivors: A teachable moment?. Gynecologic Oncology 116(Issue 3):S81-S82, 2010. e-Pub 2010.
107. Sun CC, Peterson SK, White KG, Boyd-Rogers S, Schmeler KM, Bodurka DC, Lu KH. Patient preferences for risk management strategies for women with Lynch syndrome. Familial Cancer 9(4):732-733, 2010. e-Pub 2010.
108. Gershenson DM, Sun CC, Malpica A, Deavers M, Bodurka DC, Schmeler KM. Low-grade serous primary peritoneal carcinoma. J Clin Oncol 28(15s), 2010. e-Pub 2010.
109. Bodurka D, Sun CC, Jhingran A, Urbauer D, Levenback C, Eifel P, Ramondetta L, Ramirez P, Frumovitz M, Schover L. A Longitudinal Evaluation of Sexual Functioning and Quality of Life in Cervical Cancer Survivors. Gyncologic Oncology 120(Supplement 1):S81-S82, 2010. e-Pub 2010.
110. Sun CC, Ramondetta LM, Jhingran A, Eifel PJ, Crane C, Phan AT, Frumovitz MM, Elting LS, Bodurka DC. Patient preferences for chemoradiation related side effects. Journal of Clinical Oncology 27(suppl):e20604, 2009. e-Pub 2009.
111. Tung CS, Sun CC, Cohen L, Frenkel M, Ramondetta LM, Smith JA, Parker P, Bodurka DC. Complementary and alternative medicine: What do oncology healthcare providers think?. Journal of Clinical Oncology 27(suppl):e20614, 2009. e-Pub 2009.
112. Kwon JS, Daniels MS, Sun CC, Lu KH. Opportunities for future cancer prevention by BRCA mutation testing of women with ovarian cancer. Gynecologic Oncology 112(S98), 2009. e-Pub 2009.
113. Sun CC, Aguilliard J, Jhingran A, Eifel P, Crane CH, Phan A, Ramondetta LM, Frumovitz MF, Elting L, Bodurka DC. Preferences for Side Effects of Chemoradiation: Focus on Nausea and Vomiting. Supportive Care in Cancer 16(6):734, 2008. e-Pub 2008.
114. Ramondetta L, Johnson A, Sun CC, Achanta L, Kavanagh J. A Survey On the Role of Religion and Spirituality in Gynecologic Oncologists. Supportive Care in Cancer 16(6):718, 2008. e-Pub 2008.
115. Westin SN, Sun CC, Lacour RA, Urbauer DL, Lu KH, Bodurka DC. Survivors of Gynecologic Malignancies (Gyn Ca): Impact of Treatment on Health and Well-being. Supportive Care in Cancer 16(6):752, 2008. e-Pub 2008.
116. Thaker P, Sun CC, Palmer L, Pei BL, Bruera E, Ramondetta L. Spirituality, Coping and Control In a Palliative Care Setting. Supportive Care in Cancer 16(6):719, 2008. e-Pub 2008.
117. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Kavanagh JJ. Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. Gynecologic Oncology 108(3 Supplement 1):S5, 2008. e-Pub 2008.
118. Meyer L, Westin SN, Lacour RA, Urbauer DL, Schmeler KM, Daniels MS, Sun CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: missed opportunities. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):300S, 2008. e-Pub 2008.
119. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz MM, Bodurka DC, Sood AK. Pelvic fractures following radiation therapy for cervical cancer: implications for survivors. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):300S, 2008. e-Pub 2008.
120. Westin SN, Sun CC, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz M, Lu KH, Gershenson DM, Bodurka DC. Survivors of gynecologic malignancies (GYN CA): Impact of treatment on health and well-being. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):299S, 2008. e-Pub 2008.
121. Sun CC, Westin SN, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz M, Gershenson DM, Lu KH, Bodurka DC. Health concerns of long-term survivors of gynecologic cancers. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):727S, 2008. e-Pub 2008.
122. Sun CC, Peterson S, Lu KH, White K, Daniels M, Boyd-Rogers S, Westin SN, Bodurka DC. Women’s preferences for cancer screening strategies and prophylactic surgery. Gynecologic Oncology 108(3 Supplement):S137, 2008. e-Pub 2008.
123. Lacour RA, Daniels MS, Westin SN, Meyer LA, Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-stage ovarian cancer?. Gynecologic Oncology 108(3 Supplement):S108-109, 2008. e-Pub 2008.
124. Meyer LA, Westin SN, Lacour RA, Urbauer DL, Sun CC, Daniels MS, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: Missed Opportunities. Gynecologic Oncology 108(3 Supplement):S67-68, 2008. e-Pub 2008.
125. Lacour RA, White KG, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik T, Urbauer DL, Sun CC, Bodurka DC, Gershenson DM, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology 108(3 Supplement):S59, 2008. e-Pub 2008.
126. Bodurka DC, Deavers M, Tian C, Sun CC, Ozols RF, Gershenson DM. Ancillary study of GOG 158: Survival based on reclassification to a two-tier grading system for serous carcinoma of the ovary. Gynecologic Oncology 108(3 Supplement):S33, 2008. e-Pub 2008.
127. Ostler DA, Malpica A, Sun CC, Perna AG, Diwan AH, Lazar AJ, Deavers MT, Prieto VG. Comparative study of methods to determine depth of invasion in vulvar squamous cell carcinoma. Laboratory Investigation 88(Supplement 1s):216A-217A, 2008. e-Pub 2008.
128. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation. Accepted for poster presentation at the 2007 Breast Cancer Symposium, 2007. e-Pub 2007.
129. Frumovitz M, Sun CC, Brown J, Reis D, R, Milam, M, Levenback CL, Ramirez PT. Total laparoscopic radical hysterectomy in an academic vs community setting. Journal of Minimally Invasive Gynecology 14:48, 2007. e-Pub 2007.
130. Katz, MHG, Wolff RA, Pisters PWT, Sun CC, Evans DB, Varadhachary GR, Fleming JB, Hwang RF. Borderline Resectable Pancreatic Cancer: The Importance of this Emerging Stage of Disease. Accepted for presentation at the 2007 Southern Surgical Association Annual Meeting, 2007. e-Pub 2007.
131. Lacour RA, Westin SN, Daniels MS, Milam MR, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Survival in advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5514, 2007. e-Pub 2007.
132. Burke TW, Navo MA, Smith JA, Jung MS, Broaddus R, Iyer RB, Lu KH, Sun CC, Atkinson EN, Ramondetta LM. Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5595, 2007. e-Pub 2007.
133. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5571, 2007. e-Pub 2007.
134. Sun CC, Westin SN, Lu KH, Milam MR, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Impact of BRCA 1/2 Testing: Body Image, Sexual Functioning, and Quality of Life (QOL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):1525, 2007. e-Pub 2007.
135. Westin SN, Sun CC, Lu KH, Milam MR, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Management Strategies for Women at High Risk for Breast and Ovarian Cancer: Are Women Satisfied?. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):1524, 2007. e-Pub 2007.
136. Frumovitz MF, dos Reis R, Sun CC, Milam M, Brown J, Bevers M, Ramirez PT. A Comparison of Total Laparoscopic vs. Abdominal Radical Hysterectomy for Cervical Cancer. Gynecologic Oncology 104(3S1):S25, 2007. e-Pub 2007.
137. Milam MR, Sun CC, Landen CN, Schmeler KM, Lu KH, Coleman RL, Ramirez PT. Neoadjuvant Chemotherapy Improves Perioperative Outcomes in Patients with Advanced Epithelial Ovarian Cancer. Gynecologic Oncology 104(3S1):S43, 2007. e-Pub 2007.
138. Thaker PH, Sun CC, Bodurka DC, Palmer J, Pei B, Willey J, Bruera E, Ramondetta L. Spirituality, quality of life, and locus of control in a palliative care setting. Journal of Clinical Oncology 24(18S):690S, 2006. e-Pub 2006.
139. Sun CC, Peterson SK, White KG, Watts BG, Daniels MS, Boyd-Rogers SG, Schmeler KM, Bodurka DC, Lu KH. Preferences for cancer prevention strategies in women with hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology 24(18S):1018, 2006. e-Pub 2006.
140. Schmeler K, Tortolero-Luna G, Soliman PT, Sun CC, Milam M, Slomovitz B, Gershenson D, Lu K, Williams M, Betts P. Racial/ethnic differences in survival among Texas women with ovarian cancer: A population-based study. Gynecologic Oncology 101:S63-64, 2006. e-Pub 2006.
141. Soliman PT, Morris V, Sun CC, Ramirez P, Weaver C, Jennings J, Schmeler K, Slomovitz B, Bodurka DC. No increase in risk associated with primary surgical cytoreduction in women diagnosed with ovarian cancer at an advanced age. Gynecologic Oncology 101:S143-144, 2006. e-Pub 2006.
142. Milam M, Slomovitz B, Schmeler K, Soliman PT, Ramirez P, Sun CC, Eifel P, Ramondetta L, Lu K. Management and patterns of recurrence of women with occult stage II endometrioid endometrial cancer. Gynecologic Oncology 101:S77, 2006. e-Pub 2006.
143. Thaker P, Sun CC, Bodurka DC, Palmer JL, Pei BL, Willey J, Bruera E, Ramondetta LM. Spirituality and locus of control in a palliative care setting. Gynecologic Oncology 101:S107-108, 2006. e-Pub 2006.
144. Schmeler K, Sun CC, Bodurka DC, White K, Soliman PT, Uyei AR, Erlichman J, Arun B, Peterson S, Milam M, Slomovitz B, Gershenson DM, Lu K. Are women with BRCA1/2 mutations choosing prophylactic bilateral salpingo-oophorectomy over surveillance?. Gynecologic Oncology 101:S107, 2006. e-Pub 2006.
145. Schmeler K, Broaddus R, Sun CC, Soliman PT, Milam M, Thornton A, Wu W, Slomovitz B, Gershenson D, Lu K, McCampbell A, Shipley G. Obesity-related endometrial cancers are not molecularly distinct from endometrial cancers arising in normal-weight women. Gynecologic Oncology 101:S101-102, 2006. e-Pub 2006.
146. Soliman PT, Tortolero-Luna G, Schmeler K, Milam M, Slomovitz B, Sun CC, Brown J, Gershenson D, Lu K, Williams M, Betts P. Racial/ethnic differences in survival among Texas women with endometrial cancer: A population-based study. Gynecologic Oncology 101:S80, 2006. e-Pub 2006.
147. Zighelboim I, Ramirez PT, Sun CC, Frumovitz MM, Jhingran A, Levenback C. Factors That Preclude Resection of Bulky Nodal Metastases in Patients with Cervical Cancer. Gynecologic Oncology 96:989-990, 2005. e-Pub 2005.
148. Sun CC, Bodurka DC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Preferences over time of chemo-experienced versus chemo-naïve patients for treatment-related side effects. Journal of Clinical Oncology 23(16S):784s, 2005. e-Pub 2005.
149. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Pearson HC, Berenson A, Bodurka DC. Are women ready for the cervical cancer vaccine? . Gynecologic Oncology 96:912, 2005. e-Pub 2005.
150. Slomovitz BM, Ramondetta LM, Crotzer C, Soliman P, Schmeler K, Broaddus RR, Sun CC, Gershenson DM, Burke TW, Lu KL. Clinical and pathologic review of clear cell carcinoma of the endometrium: a single institution study of 81 patients. poster presentation. 36th Annual Meeting of the Society of Gynecologic Oncologists:accepted for March 2005, 2005. e-Pub 2005.
151. Slomovitz BM, Coleman RL, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM. Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study. Journal of Clinical Oncology 23(16S):474s, 2005. e-Pub 2005.
152. Slomovitz BM, Burke TW, Soliman PT, Ramondetta LM, Eifel PJ, Jhingran A, Wolf J, Sun CC, Gershenson DM. Patterns of recurrence of uterine papillary serous carcinoma. Gynecologic Oncology 96:947, 2005. e-Pub 2005.
153. Schmeler KM, Soliman PT, Munsell MF, Daniels MS, White KG, Boyd-Rogers SG, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch syndrome/HNPCC. Journal of Clinical Oncology 23(16S):844s, 2005. e-Pub 2005.
154. Schmeler K, Soliman P, Sun CC, Oh J, Gershenson D, Slomovitz B, Lu K. Defining endometrial cancer risk factors for young, non-obese women. Gynecologic Oncology 96:1015, 2005. e-Pub 2005.
155. Lu KH, Schorge J, Rodabaugh K, Sun CC, Daniels M, White K, Soliman P, Luthra R, Broaddus R. Defining criteria for Lynch/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Journal of Clinical Oncology 23(16S):848s, 2005. e-Pub 2005.
156. Bodurka DC, Sun CC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Longitudinal assessment of quality of life of patients with ovarian cancer receiving high-dose or conventional-dose chemotherapy. Journal of Clinical Oncology 23(16S):470s, 2005. e-Pub 2005.
157. Slomovitz BM, Ramirez PT, Bodurka DC, Sun CC, Oh JC, Diaz P, Broaddus RR, Soliman PT, Gershenson DM, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? . Gynecologic Oncology 92:404-405, 2004. e-Pub 2004.
158. Slomovitz BM, Broaddus RR, Sneige N, Tarco E, Soliman PT, Wu W, Sun CC, Schmandt R, Burke TW, Gershenson DM, Lu KH. Her-2/neuexpression and amplification in uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 92:435-436, 2004. e-Pub 2004.
159. See HT, Walker PW, Palmer JL, Basen-Engquist K, Elsayem A, DeGarcia L, Sun CC, Bodurka DC, Kavanagh JJ. Palliative Care Index for Ovarian Cancer. International Gynecologic Cancer Society:544, 2004. e-Pub 2004.
160. Sun CC, Weaver CB, Fitzgerald MA, Wolf JK, Ramirez PT, Gershenson DM, Bodurka DC. Preferences (PREF) of physicians (MDs) and patients (pts) with ovarian cancer (OVCA): Who values what? . Gynecologic Oncology 92:501, 2004. e-Pub 2004.
161. Schmeler K, Soliman P, Sun C, Oh J, Slomovitz B, Lu K. Risk factors for endometrial cancer in young, premenopausal, non-obese women. poster presentation. Third Annual American Association for Cancer Research International Conference: Frontiers in Cancer Prevention Research, 2004. e-Pub 2004.
162. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/NEU, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progresterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. International Gynecologic Cancer Society:222, 2004. e-Pub 2004.
163. Schimp VL, Sun CC, Jennings J, Soliman P, Bodurka DC. Bowel Obstruction in Ovarian Cancer Patients: Surgical versus Medical Therapy. Gynecologic Oncology 92:453, 2004. e-Pub 2004.
164. Jhingran A, Bodurka DC, Sun CC, Eifel PJ. Acute toxicity of chemoradiation for cervical cancer. American Radium Society, Napa Valley, CA, 2004. e-Pub 2004.
165. Jenkins AD, Ramondetta L, Johnston T, Sun CC, Wolf JK, Bodurka DC, Atkinson EN, Levenback CF. A Phase II Study of Capecitabine in Recurrent Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology 92:427, 2004. e-Pub 2004.
166. Frumovitz M, Sun CC, Schover LR, Jhingran A, Eifel PJ, Bevers TB, Levenback C, Bodurka DC. Quality of Life in Cervix Cancer Survivors: Five Years Posttreatment. Gynecologic Oncology 92:474, 2004. e-Pub 2004.
167. Frumovitz M, Slomovitz BM, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Endometrial cancer: To stage or not to stage, part II. Gynecologic Oncology 92:487, 2004. e-Pub 2004.
168. Soliman PT, Slomovitz BM, Sun CC, Gershenson DM, Lu KH. Endometrial cancer screening should be considered in women with colon cancer and one family member with an HNPCC-associated Cancer. Gynecologic Oncology 92:434, 2004. e-Pub 2004.
169. Soliman PT, Slomovitz BM, Broaddus R, Sun CC, Oh J, Gershenson DM, Lu KH. Synchronous Primary Cancers of the Endometrium and Ovary: A single institution review of 75 cases. Gynecologic Oncology 92:482-483, 2004. e-Pub 2004.
170. Slomovitz BM, Wu W, Soliman PT, Broaddus RR, Sun CC, Bodurka DC, Gershenson DM, Lu KH. Clinical and molecular characteristics of patients who develop breast cancer and uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 92:423-424, 2004. e-Pub 2004.
171. Tseng JF, Sun CC, Abdalla EK, Vauthey J, Pisters PW, Lee JE, Evans DB. Resection of the Superior Mesenteric-Portal Vein for Pancreatic Adenocarcinoma: Margin Status and Survival Duration. Gastroenterology 126(4, Suppl.2):A-769, 2004. e-Pub 2004.
172. Shvartsman HS, Bodurka D, Sun CC, Crispens M, Lu K, Silva E, Gershenson D. Comparative study of disease process and survival in patients with recurrent serous low malignant potential tumor of ovary versus patients with low grade serous carcinoma of the ovary. Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:452, 2004. e-Pub 2004.
173. Tseng JF, Kronowitz, SJ, Hunt KK, Sun CC, Babiera GV, Singletary E, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The Rate of Immediate Reconstruction Following Mastectomy for Breast Cancer Varies by Patient Race. Annals of Surgical Oncology 11(Suppl 2):S32, 2004. e-Pub 2004.
174. Weaver C, Sun CC, Schover LR, Aday L, Bodurka DC. Assessment of quality of life and sexual activity after treatment for cervix cancer. AcademyHealth 20th Annual Research Meeting, CD-ROM Conference Proceedings:43, 2003. e-Pub 2003.
175. Bodurka DC, Frumovitz M, Sun CC, Ramirez PT, Bevers MW, Gershenson DM. Laparoscopy For Probable Ovarian Cancer: Less May Not Be More. Gynecologic Oncology 88(2):244, 2003. e-Pub 2003.
176. Sun CC, Bodurka DC, Lu KH, Efron B, Andersen A, Bevers TBB, Gershenson DM, Bast RC. Perceptions of OVCA Risk and Screening: Differences between women with a history of breast cancer (WHxBr) and women with no history of breast cancer (WnoBr). Gynecologic Oncology 88(2):239-240, 2003. e-Pub 2003.
177. Ramirez PT, Vidal C, Schimp VL, Sun CC, Slomovitz BM, Bevers MW, Bodurka DC. Indications and Outcomes of Hysteroscopy and Hysterectomy in Breast Cancer Patients. Gynecologic Oncology 88(2):216, 2003. e-Pub 2003.
178. Schimp VL, Sun CC, Wolf JK, Bodurka DC, Levenback CL, Ramirez PT. Vacuum-Assisted Closure in the Treatment of Gynecologic Oncology Wound Failures. Gynecologic Oncology 88(2):203-204, 2003. e-Pub 2003.
179. Frumovitz M, Ramirez PT, Tortolero-Luna G, Bodurka DC, Sun CC, Malpica A, Levenback C. Groin recurrence in patients who underwent lymphatic mapping for vulvar malignancy. Int J Gyn Cancer 13(Supp 1):17, 2003. e-Pub 2003.
180. Bodurka DC, Sun CC, Weaver CB, Jennings J, Melancon CH, Bevers MW, Wolf JW, Ramirez PT, Gershenson DM, Lairson DR. Ovarian cancer (OV CA): The cost of caregiving. Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:527, 2003. e-Pub 2003.
181. Sun CCS, Slomovitz BM, Frumovitz M, Weaver CB, Lu KH, Gershenson, DM, Bodurka DC. Preference (utility) assessment in patients with gynecologic malignancies: The M. D. Anderson Experience. European Journal of Cancer Supplements 1(3):S16, 2003. e-Pub 2003.
182. Sun CC, Bodurka DC, Weaver C, Andersen R, Gershenson DM, Bast RC. Knowledge of ovarian cancer screening in a low-risk population. AcademyHealth 20th Annual Research Meeting, CD-ROM Conference Proceedings:39, 2003. e-Pub 2003.
183. Sun CC, Bodurka DC, Weaver CB, Fitzgerald MA, Wolf JK, Levenback C, Kavanagh JJ, Palmer L, Gershenson DM, Rubenstein EB. Preferences (PREF) for Side Effects (SEs) of Chemotherapy (CHEMO): How Long is Too Long and How Much is Too Much? . Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:743, 2003. e-Pub 2003.
184. Lu K, Beahm E, Arun B, Bodurka-Bevers D, Sun CC, Miller M, Hunt K, Ames F, Strong L, Meric-Bernstam, F. Coordinated Prophylactic Surgical Management for Women with Breast-Ovarian Cancer Syndrome. Proceedings of the 2nd Annual International Conference on Frontiers in Cancer Prevention Research:100 (# C190), 2003. e-Pub 2003.
185. Sun CC, Borden CL, Young VN, Charneco L, Rojas M, Lerten F, Goldstein S, Morris M, Gershenson DM, Bodurka DC. A feasibility study of assessing patient preferences and quality of life in culturally-diverse women with cervix cancer. Academy for Health Services Research and Health Policy Annual Meeting, CD-ROM Conference Proceedings. Part 1 1:48, 2002. e-Pub 2002.
186. Anderson ML, Bodurka DC, White K, Sun CC, Wolf JK, Burke TW. Outcome of patients undergoing surgical resection of recurrent leiomyosarcoma. Gynecologic Oncology 84(3):528, 2002. e-Pub 2002.
187. Sun CC, Bodurka DC, Donato ML, Borden C, Rubenstein EB. Nausea and vomiting side-effects of cancer therapies: preference assessments from patients, health care providers and healthy women. Supportive Care in Cancer 10(4):378, 2002. e-Pub 2002.
188. Sun CC, Bodurka DC, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. 3rd Annual Kelsey Research Foundation's Health Services and Outcomes Research Conference, 2002. e-Pub 2002.
189. Sun CC, Borden CL, Donato ML, Cooke S, Basen-Engquist K, Fitzgerald MA, Kavanagh JJ, Gershenson DM, Bodurka DC. Patient preferences for side-effects of chemotherapy for ovarian cancer: do preferences change over time? . Gynecologic Oncology 84(3):493, 2002. e-Pub 2002.
190. Sun CC, Borden CL, Charneco L, Young VN, Rojas M, Lerten F, Goldstein S, Morris M, Gershenson DM, Bodurka DC. Chemoradiation for cervix cancer: cultural differences in preferences for side-effects. Programs/Proceedings of the American Society for Clinical Oncology, 38th Annual Meeting. Publication number 2599 21(2), 2002. e-Pub 2002.
191. Wolf JK, Sun CC, Verschraegen CF, Jenkins AD, Branham DW, Bodurka DC. A phase II study of Xeloda in patients with chemotherapy resistant recurrent ovarian cancers. Programs/Proceedings of the American Society for Clinical Oncology, 38th Annual Meeting. Publication number 893 21(1), 2002. e-Pub 2002.
192. Sun CC, Bodurka-Bevers, D, Borden CL, Rojas MS, Lerten F, Goldstein S, Gershenson DM, Morris M. A Pilot Study to Assess Patient Preferences for Side Effects of Chemoradiation. Gynecologic Oncology 80(2):288, 2001. e-Pub 2001.
193. Sun CC, Donato ML, Cooke S, Borden CL, Basen-Engquist K, Fitzgerald MA, Kavanagh JJ, Gershenson DM, Bodurka-Bevers D. Ovarian Cancer (OVCA) Patients (PTS) Undergoing High-Dose Chemotherapy (HDCT) With Peripheral Blood Stem Cell Support (PBSCS): Preferences For Toxicities Over Time. Programs/Proceedings of the American Society for Clinical Oncology, 37th Annual Meeting:Publication # 2576, 2001. e-Pub 2001.
194. Sun CC, Bodurka-Bevers, Gershenson DM, Lairson DL. Estimating Quality-Adjusted Survival For Women at High-Risk for Developing Breast Cancer: A Monte Carlo Markov Model Incorporating 3 Different Sets of Preferences. Academy for Health Services Research and Health Policy Annual Meeting CD-ROM Conference Proceedings:Abstract #67, 2001. e-Pub 2001.
195. Sun CC, Bodurka-Bevers D, Borden CL, Cantor SB, Rieger PT, Mills GB, Gershenson DM, Lairson DR. Do Preferences Vary By Method of Preference Assessment or Patient Group?. Medical Decision Making 20(4):482, 2000. e-Pub 2000.
196. Sun CC, Bodurka-Bevers DC, Rieger P, Martin CG, Mills GB, Gershenson DM, Cantor SB. Patient Preferences for Outcomes in Women at High-Risk for Breast/Ovarian Cancer – Who and How You Ask Matters. Program/Proceedings of the American Society of Clinical Oncology 19:435a, 2000. e-Pub 2000.
197. Bodurka-Bevers, DC, Sun CC, Cantor SB, Rieger P, Martin CG, Mills GB, Gershenson DM. Preferences Over Time of Women at High-Risk of Breast/Ovarian Cancer Who Undergo Genetic Counseling/Ovarian Cancer Screening. Program/Proceedings of the American Society of Clinical Oncology 19:444a, 2000. e-Pub 2000.
198. Sun CC, Bodurka-Bevers D, Cantor SB, Gershenson DM, Lairson D. Preferences Using Standard Gamble and Time Trade-off: Societal versus Patient Perspectives. Association for Health Services Research Annual Meeting CD-ROM Conference Proceedings:Abstract #93, 2000. e-Pub 2000.
199. Bratka CS, Elting L, Martin C, Chau Q, Rubenstein EB. Patients’ Ratings of Illness and Stability, Correlation with Clinicians’ Ratings and Emergency Center Outcomes. Supportive Care in Cancer 5(2):173, 1997. e-Pub 1997.
200. Bratka C, Rubenstein E, Martin C, Chau Q, Elting L. Predicting Emergency Center (EC) Outcomes For Cancer Patients (pts). Program/Proceedings of the American Society of Clinical Oncology 16:422a, 1997. e-Pub 1997.
201. Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI. Economic Evaluation of Management Strategies for Low-Risk Febrile Neutropenic Cancer Patients. Program/Proceedings of the American Society of Clinical Oncology 16:419a, 1997. e-Pub 1997.
202. Cantor SB, Bratka CS, Richards-Kortum R, Mitchell MF. A ‘league table’ for receiver operating characteristic curve analysis? . Medical Decision Making 16:466, 1996. e-Pub 1996.

Book Chapters

1. Bodurka DC, Sun CC, Basen-Engquist KM. Quality of Life in the Gynecologic Cancer Patient. In: Gynecologic Cancer: Controversies in Management. Elsevier Ltd, 785-794, 2004.
2. Bodurka DC, Sun CC. Quality of Life and Sexual Functioning. In: Gynecologic Cancer, in press, 2000.
3. Rubenstein EB, Elting LS, Sun CC, Rolston KVI. Outpatient Management of Neutropenic Fever: Antibiotics, Growth Factors or Both? . In: Clinical Applications of Cytokines and Growth Factors. Kluwer Academic Publishers, 1998.
4. Rubenstein EB, Sun CC. Outpatient Management of Chemotherapy-Treated Patients. In: Supportive Care in Cancer: A Handbook for Oncologists. Marcel Dekker, Inc, 1998.